Skip Content
Page Banner Image

In the Know – January 2018

Volume 13, Issue 1



Looking Back at 2017

Your generous support has made 2017 a momentous year. You show a strong commitment to improving the lives of individuals affected by HD and provide substantive hope for the future. Click here to see the highlights from 2017.

Let’s Live for Today… Music Therapy and HD

Vicki St. Amand’s journey with HD has not been easy. Music therapy has helped her to channel her feelings and control emotional expression. Click here to read her story and watch Vicki preform her song.

Horizon Winter 2018 Edition Out Now!

Chapter Champions, The Latest Scoop on Clinical Trials, Looking Back at YPAHD Day 2017… The Winter 2018 edition of our quarterly newsletter, Horizon, is out now and contains all these great articles and more. Click here to read the latest edition.

Amaryllis Photo Festival

Our 2017 Amaryllis Photo Festival is in full swing with some great pictures already submitted. Click here to learn more and participate in this fun festival.

Champions of Hope

Thanks to our Champion of Hope monthly donors for continuing to create a real difference and inspiring hope in the HD community in this new year. Our Champions’ ongoing support is enabling breakthrough research and providing much needed services to individuals and families every single day. Click here to be our next Champion of Hope.


Keep up to date on the latest developments in genetic fairness. Click here for the most recent information.


Five Amazing Things That Happened in 2017
BBC – December 28, 2017

BBC rounded up the top five amazing things to happen in 2017 with the Huntingtin Lowering trial landing at number 2! In comparison, Prince Harry and Meghan Markle’s engagement fell at number 5. Click here to see the full list.

Ask the Expert: Q&A on the Huntington-Lowering Trial Program
HDBuzz – December 18, 2017

The research news, announced on 11 December 2017, that a research team from the Huntington’s Disease Centre at University College London have made significant step towards a possible treatment for Huntington’s disease, raised many questions for the Huntington’s disease community. Dr Ed Wild answered some of these questions on behalf of the UK HD Association, helping to give some context to what this news means for people affected by Huntington’s now and in the future. Click here to read the full Q&A.

Roche Snaps up Huntington’s Drug on Positive Data
BioPharmaDIVE – December 13, 2017

Swiss pharma Roche AG will license a experimental Huntington’s disease drug developed by Ionis Pharmaceuticals Inc., assuming responsibility for all future development and commercialization in exchange for a $45 million licensing fee paid to Ionis. Click here to read the full article.

Update: Measuring DNA Repair Capacity and Visualizing Huntingtin in HD Patient Cells
Ray Truant Laboratory – January 8, 2018

Dr. Tamara Maiuri of Ray Truant’s lab at McMaster University provides an update on her research: “Previously I described a method to measure DNA repair capacity in cells: the GFP reactivation assay. This worked nicely in mouse striatal cells, with HD cells consistently showing about half the repair capacity of wild type cells. I have since tried it in cells from HD patients, using a different method to measure the GFP signal (microscopy instead of flow cytometry).” Click here to read the full update.

Researchers Identify Markers to Track Huntington’s Years Before Signs of Disease
Huntington’s Disease News – January 4, 2018

Researchers found biomarkers — molecules with elevated levels — in people who carry the Huntington’s disease (HD) gene who have not yet shown symptoms of the disease. These markers may allow for the testing of new treatments before the onset of Huntington’s in susceptible individuals. Click here to read the full article.

HSC Funded Researcher, Stephen Ferguson, Findings on Mouse Model
Science Mag – December 19, 2017

We found that the treatment of 12-month-old symptomatic heterozygous and homozygous zQ175huntingtin knockin mice for 12 weeks with CTEP, a negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), reduced the size and number of huntingtin aggregates. Click here to read the full publication.

Enroll-HD – December 2017

Click here to check out the latest updates in Enroll-HD’s monthly bulletin.



We support those facing huntington disease
 Latest Blog


Let Us Know How We Can Help
Enter your name, email address and question(s) below for assistance.



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up